Strata Critical Medical (SRTA)
NASDAQ:SRTA
Want to see SRTA full AI Analyst Report?
SRTA Stock Chart & Stats
$4.57
--
Market closed
$4.57
--
Day’s Range― - ―
52-Week Range$2.73 - $6.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)632.45K
Market Cap
$433.96M
Enterprise Value$395.93M
Total Cash (Recent Filing)$61.23M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)9.6
Beta2.02
Next Earnings
May 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding86,446,690
10 Day Avg. Volume645,202
30 Day Avg. Volume632,445
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.78
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit9.63
Enterprise Value/Ebitda-21.44
Forecast
1Y Price Target
$9.08Price Target Upside98.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$269.18M
Bulls Say, Bears Say
Bulls Say
Balance-sheet Liquidity & Low LeverageA no-debt position with ~ $61M cash and an undrawn asset-based facility materially increases financial flexibility. This durable liquidity buffer lowers refinancing and solvency risk, enabling continued organic investments, M&A activity, and the ability to absorb integration timing shocks without forcing dilutive financing.
Margin Recovery And Raised EBITDA GuidanceSequential and year-over-year adjusted EBITDA improvement plus higher 2026 guidance signal structural margin recovery from logistics scale, Keystone benefits, and pricing/mix. Sustained progress in adjusted EBITDA suggests durable operating leverage if management converts improvements into consistent operating cash generation over subsequent quarters.
Organic Logistics Growth And M&A PlatformStrong organic logistics growth (~35% in Q4) combined with a functioning M&A pipeline and an undrawn $30M facility creates a repeatable growth engine. Durable impact: acquisitions and integration capacity can accelerate scale, diversify revenue mix (clinical perfusion), and lift margins if execution remains disciplined and fleet strategy preserves asset-light flexibility.
Bears Say
Persistent Negative Operating Cash FlowChronic negative operating cash flow means the business consumes liquidity to fund growth and integration. Over months this raises reliance on the balance sheet, credit lines, or earn-outs; it can constrain reinvestment and make the company vulnerable if M&A or growth slows, limiting long-term self-funding capacity.
Core Operating Losses And Revenue DeclineNegative operating profits and a recent revenue drop indicate the core business has not yet achieved durable profitability. The 2025 revenue contraction and persistent negative EBIT/EBITDA imply returns remain weak; until operating margins and top-line stability are consistent, net income swings may be driven by non‑operating items rather than sustainable operations.
Integration Costs, Contingent Obligations & Asset RiskSignificant contingent liabilities (earn-outs) plus recent one‑off integration costs and an aircraft write-down create execution and cash-timing risk. These obligations can reduce available cash for organic investment or acquisitions, complicate planning, and amplify funding needs if operating cash flow does not improve sustainably.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical’s price range in the past 12 months?
Strata Critical Medical lowest stock price was $2.73 and its highest was $6.02 in the past 12 months.
What is Strata Critical Medical’s market cap?
Strata Critical Medical’s market cap is $433.96M.
When is Strata Critical Medical’s upcoming earnings report date?
Strata Critical Medical’s upcoming earnings report date is May 06, 2026 which is in 4 days.
How were Strata Critical Medical’s earnings last quarter?
Strata Critical Medical released its earnings results on Mar 03, 2026. The company reported -$0.062 earnings per share for the quarter, missing the consensus estimate of $0.01 by -$0.072.
Is Strata Critical Medical overvalued?
According to Wall Street analysts Strata Critical Medical’s price is currently Undervalued.
Does Strata Critical Medical pay dividends?
Strata Critical Medical does not currently pay dividends.
What is Strata Critical Medical’s EPS estimate?
Strata Critical Medical’s EPS estimate is -0.04.
How many shares outstanding does Strata Critical Medical have?
Strata Critical Medical has 86,446,690 shares outstanding.
What happened to Strata Critical Medical’s price movement after its last earnings report?
Strata Critical Medical reported an EPS of -$0.062 in its last earnings report, missing expectations of $0.01. Following the earnings report the stock price went up 6.904%.
Which hedge fund is a major shareholder of Strata Critical Medical?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.08 (98.76% Upside)
$9.08 (98.76% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
74.42%
12-Months-Change
Fundamentals
Return on Equity
16.46%
Trailing 12-Months
Asset Growth
29.27%
Trailing 12-Months
Company Description
Strata Critical Medical
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and financial improvement driven by robust organic logistics growth (35%+), a successful integration of the Keystone acquisition, significant gross profit and adjusted EBITDA improvement, and raised 2026 guidance. Key positives include no debt, a healthy cash balance (~$61M), an active M&A pipeline supported by an undrawn $30M facility, and regulatory trends that favor the company's DCD/NRP capabilities. Near-term weaknesses are largely execution and timing-related: a negative operating cash flow in Q4 driven by nonrecurring charges and working capital build from integration, a discrete aircraft corrosion/write-down, elevated SG&A from Keystone, and an anticipated sequential margin dip in Q1 due to mix and weather. Overall, the positives (sizable growth, margin improvement, guidance raises, strong balance sheet and strategic positioning) substantially outweigh the transient and integration-related lowlights.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$9.08
▲(98.76% Upside)
Technical Analysis
―
AerSale Corporation
―
Sun Country Airlines Holdings
―
flyExclusive
―
Surf Air Mobility, Inc.
―
Ownership Overview
15.08% Insiders
11.09% Mutual Funds
2.15% Other Institutional Investors
55.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---